Showing 1 - 20 results of 262,935 for search '(((( 2 d decrease ) OR ( 10 ((a decrease) OR (_ decrease)) ))) OR ( 16 _ decrease ))*', query time: 2.31s Refine Results
  1. 1
  2. 2
  3. 3

    TMEM16A knockdown decreased activation of the MEK-ERK1/2 pathway and expression of cyclin D1. by Yujie Sui (549090)

    Published 2014
    “…<p>Western blot results show inhibition of TMEM16A led to a decrease in phospho-MEK, phospho-ERK1/2 and cyclin D1. …”
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Overexpression of a dominant negative alpha2-annexin::GFP (D122A, D275A) decreases ventral flagellar waveform amplitude with only slight decreases in attachment. by Susan A. House (191265)

    Published 2011
    “…(<b>B</b>) Overexpression of the dominant negative alpha2-annexin (D122A, D275A), or alpha2-annexin dn, results in a ventral flagellar (vf) beat with significantly decreased amplitude (n = 25; see also <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1002167#ppat.1002167.s004" target="_blank">Video S3</a>). …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    dMi-2 decreases the stability and extent of cohesin chromosome binding. by Barbara Fasulo (144611)

    Published 2012
    “…<p>(A) FRAP recovery curves for EGFP-Smc1 in wild-type salivary gland nuclei, and salivary gland nuclei in which <i>da-GAL4</i> drives the expression of two <i>UAS-dMi-2<sup>+</sup></i> transgenes (<i>EGFP-Smc1 da-GAL4/UAS-dMi-2<sup>+</sup> 3-3; UAS-dMi-2<sup>+</sup> 15-1/+</i>) at 25°C. …”
  15. 15
  16. 16
  17. 17
  18. 18

    Decreased Sho levels in ScN2a-Sho cells. by Joel C. Watts (195735)

    Published 2011
    “…(<b>C</b>) Quantification of Sho levels in ScN2a-Sho-1 (<i>n</i> = 10) and ScN2a-Sho-2 (<i>n</i> = 5) subclones revealed a significant decrease of 40–45% compared to the uninfected parental cell line (<i>n</i> = 15) (***<i>P</i><0.001).…”
  19. 19
  20. 20

    B2 decreases glycolytic intermediates in cells. by Craig Eyster (392633)

    Published 2025
    “…The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”